S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68

GoodRx Price Target, Predictions & Analyst Ratings

$7.97
-0.15 (-1.85%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$7.63
$8.41
50-Day Range
$7.74
$20.02
52-Week Range
$7.33
$48.05
Volume
2.73 million shs
Average Volume
3.25 million shs
Market Capitalization
$3.16 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.29

GoodRx (NASDAQ:GDRX) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analyst Rating Consensus

Hold
Based on 17 Analyst Ratings

Analyst Price Target Consensus

$21.74
172.71% Upside

High PT$47.00
Average PT$21.74
Low PT$8.00
TypeCurrent
5/22/21 to 5/22/22
1 Month Ago
4/22/21 to 4/22/22
3 Months Ago
2/21/21 to 2/21/22
1 Year Ago
5/22/20 to 5/22/21
Consensus Rating
Hold
Buy
Buy
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
11 Buy rating(s)
10 Buy rating(s)
7 Buy rating(s)
Hold
9 Hold rating(s)
6 Hold rating(s)
3 Hold rating(s)
6 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$21.74$30.22$45.38$49.50
Price Target Upside172.71% Upside45.93% Upside30.16% Upside29.62% Upside
Get GoodRx Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for GDRX and its competitors with MarketBeat's FREE daily newsletter.


Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

GoodRx (NASDAQ:GDRX) vs. Its Competitors

TypeGoodRxMedical CompaniesS&P 500
Consensus Rating Score
2.35
2.72
2.52
Consensus RatingHoldBuyBuy
Price Target Upside172.71% Upside459.13% Upside29.08% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News
MarketBeat
Community Rating
Outperform Votes
48
51.06%
Underperform Votes
46
48.94%
Avg. Outperform Votes
170
67.19%
Avg. Underperform Votes
83
32.81%
Avg. Outperform Votes
839
69.28%
Avg. Underperform Votes
372
30.72%

GoodRx (NASDAQ:GDRX) Analyst Ratings History

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/20/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetEqual Weight$19.00 ➝ $10.50+29.79%
5/12/2022Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Stan Berenshteyn
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price Target$20.00 ➝ $9.00+16.28%
5/11/2022Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price Target$20.00 ➝ $10.00+25.47%
5/11/2022Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price Target$22.00 ➝ $10.00+25.47%
5/10/2022Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price Target$28.00 ➝ $15.00+39.53%
5/10/2022SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Davis
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform$33.00 ➝ $10.00-6.98%
5/10/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform
5/10/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Sector Perform$35.00 ➝ $8.00-25.58%
4/6/2022Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$24.00+28.21%
4/5/2022Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Vikram Kesavabhotla
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price Target$17.00 ➝ $23.00+14.89%
3/1/2022JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetUnderweight$33.00 ➝ $20.00+19.40%
3/1/2022Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetOutperform$47.00 ➝ $28.00+67.16%
3/1/2022Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetNeutral$42.00 ➝ $28.00+67.16%
3/1/2022The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Price TargetBuy$43.00 ➝ $30.00+79.53%
3/1/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOutperform ➝ Market Perform$49.00 ➝ $22.00-19.71%
12/21/2021Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$45.00+33.57%
12/1/2021Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$47.00+23.46%
5/14/2021Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Price TargetBuy$53.00 ➝ $70.00+147.61%
10/19/2020UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$64.00+20.71%
(Data available from 5/22/2017 forward. View 10+ years of historical ratings with our analyst ratings screener.)












GoodRx (NASDAQ:GDRX) Analyst Ratings Frequently Asked Questions

What is GoodRx's consensus rating and price target?

According to the issued ratings of 17 analysts in the last year, the consensus rating for GoodRx stock is Hold based on the current 1 sell rating, 9 hold ratings and 7 buy ratings for GDRX. The average twelve-month price target for GoodRx is $21.74 with a high price target of $47.00 and a low price target of $8.00. Learn more on GDRX's analyst rating history.

Do Wall Street analysts like GoodRx more than its competitors?

Analysts like GoodRx stock less than the stock of other Medical companies. The consensus rating for GoodRx is Hold while the average consensus rating for medical companies is Buy. Learn more on how GDRX compares to other companies.

Do MarketBeat users like GoodRx more than its competitors?

MarketBeat users like GoodRx stock less than the stock of other Medical companies. 51.06% of MarketBeat users gave GoodRx an outperform vote while medical companies recieve an average of 67.19% outperform votes by MarketBeat users.

Is GoodRx being upgraded or downgraded by Wall Street analysts?

Over the previous 90 days, GoodRx's stock had 5 downgrades and 1 upgrade by analysts.

Does GoodRx's stock price have much upside?

According to analysts, GoodRx's stock has a predicted upside of 23.85% based on their 12-month price targets.

This page was last updated on 5/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.